September 2024

Symposium to Honor Prof. David Evans: Using Synthetic Biology to Battle Mpox

August 2024

MHSRS 2024: Integrating Automated High-Throughput Scratch Assay and Cell Painting for Comprehensive Analysis of Cell Migration and Wound Healing

August 2024

MHSRS 2024: Two Clinical Trials of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Military-Related Posttraumatic Stress Disorder (PTSD) Provide Rationale to Study TNX-102 SL in the Aftermath of Trauma to Reduce Acute Stress Disorder (ASD) and Prevent PTSD

August 2024

MHSRS 2024: Development of the AURORA Platform Trial Network to Test Interventions to Reduce Acute Stress Reaction Symptoms, and Illustration of Use Testing Sublingual Cyclobenzaprine TNX-102 SL

August 2024

MHSRS 2024: TNX-102 SL for Fibromyalgia

August 2024

IASP 2024: Targeting Fibromyalgia Non-Restorative Sleep with Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl): Results of the Positive Phase 3 RESILIENT Trial Consistent with Syndromal Improvement

June 2024

Vaccine Congress 2024: Horsepox: A Live Virus, Single-Dose Vaccine Platform

June 2024

AHS 2024: American Headache Society Consensus Statement and Other Recommendations: How Many Practitioners Comply With the Recommendations?

June 2024

EULAR 2024: Targeting Non-Restorative Sleep in Fibromyalgia with Bedtime TNX-102 SL (Sublingual Cyclobenzaprine HCl) Significantly Improves Pain in RESILIENT, a Confirmatory Phase 3 Randomized Clinical Trial

June 2024

American Transplant Congress 2024: Combined blockade of CD154 and CD28 co-stimulation pathways attenuates pathogenic alloimmunityand prolongs survival in cynomolgus cardiac allografts